has announced the purchase of Siascopy, including its proprietary non-invasive imaging system MoleMate for diagnosis of dermatalogical issues such as moles and lesions. MoleMate has already received approvals in the United States, and MedX intends to begin marketing and sales of the product to American physicians within a matter of weeks.
"The FDA approved MoleMate Skin Imaging System is a significant advance in the early detection of potentially life threatening moles and lesions. Physicians have also found the hand-held device easy to learn and use, and that it rapidly provides accurate images of the pigment, blood, and collagen below the mole or lesion. Now, for the first time, physicians can more accurately evaluate suspicious moles and lesions in a non-invasive, pain-free way. Experts also believe it may reduce the need for time consuming and expensive biopsies," Steve Guillen, President and CEO of MedX Health Corp, said in his statement announcing the purchase.
MedX is a 12-year-old company that designs, manufactures and distributes a range of light- and laser-based non-invasive therapeutic tools, including "laser accupuncture" treatements marketed for addiction therapy, dental, vetrinary and arthritic and muscle therapies.
Writer: Edward Keenan
Source: Steve Guillen, President and Chief Executive Officer, MedX Health Corp.